Literature DB >> 16378016

Prediction of visual field defects on standard automated perimetry by screening C-20-1 frequency doubling technology perimetry.

Maria E G Kamantigue1, Peter J Joson, Philip P Chen.   

Abstract

PURPOSE: To determine if perimetric defects, initially seen with C-20-1 frequency doubling technology (FDT) in eyes with normal standard automated perimetry (SAP), will subsequently develop on standard automated perimetry.
METHODS: Review of patients considered high-risk glaucoma suspects (GS) or with ocular hypertension (OHT), who underwent one C-20-1 FDT in 1997 or 1998. An abnormal frequency doubling technology was defined in two ways, as having either at least one, or at least two abnormal locations. An abnormal standard automated perimetry was defined as fulfilling two of three modified Anderson criteria for abnormality on two consecutive tests and at final standard automated perimetry.
RESULTS: Of 63 eyes (50 patients), 18 (28.6%) had >or=1 FDT defects, and 12 (19.0%) had >or=2 defects. After follow-up of 62 +/- 26 months, an abnormal standard automated perimetry developed in 5 eyes (28%) with frequency doubling technology defects at 22 +/- 13 months (28% of eyes with >or=1 defect and 42% of eyes with >or=2 FDT defects), and in 4 of 45 eyes (9%) with normal frequency doubling technology at 32 +/- 30 months. Kaplan-Meier survival analysis revealed the risk of an abnormal standard automated perimetry at 5 years with <or=1 FDT defect, no defects, >or=1 defects, and >or=2 defects, was 10.3%, 11.8%, 30.6%, and 46.4% respectively (P = 0.060 for >or=1 defects compared with no defects; P = 0.002 for >or=2 defects compared with <or=1 defect).
CONCLUSIONS: Abnormal results on C-20-1 frequency doubling technology perimetry predicted glaucomatous visual field loss on standard automated perimetry in some patients in this patient population, though a relatively high false positive rate was noted. Abnormality on C-20-1 frequency doubling technology warrants close observation, and further prospective evaluation is warranted.

Entities:  

Mesh:

Year:  2006        PMID: 16378016     DOI: 10.1097/01.ijg.0000196621.41991.ff

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  6 in total

1.  Frequency-doubling technology and retinal measurements with spectral-domain optical coherence tomography in preperimetric glaucoma.

Authors:  Takafumi Hirashima; Masanori Hangai; Masayuki Nukada; Noriko Nakano; Satoshi Morooka; Tadamichi Akagi; Atsushi Nonaka; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-06-12       Impact factor: 3.117

2.  The distribution of visual field defects per quadrant in standard automated perimetry as compared to frequency doubling technology perimetry.

Authors:  Wadih M Zein; Ziad F Bashshur; Rola F Jaafar; Baha' N Noureddin
Journal:  Int Ophthalmol       Date:  2010-10-06       Impact factor: 2.031

3.  Predicting progression of glaucoma from rates of frequency doubling technology perimetry change.

Authors:  Daniel Meira-Freitas; Andrew J Tatham; Renato Lisboa; Tung-Mei Kuang; Linda M Zangwill; Robert N Weinreb; Christopher A Girkin; Jeffrey M Liebmann; Felipe A Medeiros
Journal:  Ophthalmology       Date:  2013-11-26       Impact factor: 12.079

4.  Comparison of frequency doubling and flicker defined form perimetry in early glaucoma.

Authors:  Folkert K Horn; Vicki Scharch; Christian Y Mardin; Robert Lämmer; Jan Kremers
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-17       Impact factor: 3.117

5.  Structural and functional relationships in glaucoma using standard automated perimetry and the Humphrey Matrix.

Authors:  Seong Bae Park; Yoon Pyo Nam; Kyung Rim Sung; Michael S Kook
Journal:  Korean J Ophthalmol       Date:  2009-09-08

6.  Applications of Isolated-Check Visual Evoked Potential in Early Stage of Open-Angle Glaucoma Patients.

Authors:  Xiang Fan; Ling-Ling Wu; Xia Di; Tong Ding; Ai-Hua Ding
Journal:  Chin Med J (Engl)       Date:  2018-10-20       Impact factor: 2.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.